7-亚甲基双环[3.3.1]壬-3-酮 | 17933-29-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 7-亚甲基双环[3.3.1]壬-3-酮
• 中文别名: 3-亚甲基双环[3.3.1]-7-壬酮；3-亚甲基双环壬-7-酮
• 英文名称: 7-methylenebicyclo[3.3.1]nonan-3-one
• 英文别名: 7-methylidenebicyclo[3.3.1]nonan-3-one
• CAS: 17933-29-8
• 化学式: C₁₀H₁₄O
• mdl: MFCD00180664
• 分子量: 150.221
• InChiKey: YEYBYPNZUQHDMO-UHFFFAOYSA-N

物化性质

• 熔点：
  150-155
• 沸点：
  236.3±29.0 °C(Predicted)
• 密度：
  1.00±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2914299000
• 安全说明：
  S24/25
• 储存条件：
  存储条件：2-8°C，密封保存，置于干燥处。

SDS

Name:	7-Methylidenebicyclo[3.3.1]nonan-3-one 97% Material Safety Data Sheet
Synonym:
CAS:	17933-29-8

Section 1 - Chemical Product MSDS Name:7-Methylidenebicyclo[3.3.1]nonan-3-one 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
17933-29-8	7-Methylidenebicyclo[3.3.1]nonan-3-one	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 17933-29-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: cream
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 150 - 155 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H14O
Molecular Weight: 150

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, acrid smoke and fumes.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 17933-29-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
7-Methylidenebicyclo[3.3.1]nonan-3-one - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 17933-29-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 17933-29-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 17933-29-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  7-亚甲基双环[3.3.1]壬-3-酮 在 吡啶 、 lithium aluminium tetrahydride 、 对甲苯磺酰氯 、 lithium chloride 作用下， 以 四氢呋喃 为溶剂， 反应 29.0h， 生成 1-氯金刚烷
  参考文献：
  名称：

  Radical Rearrangements for the Chemical Vapor Deposition of Diamond

  摘要：

  A combination of chemical trapping and computations is used to determine the activation parameters far the interconversion of the 3-methylenebicyclo[3.3.1]nonan-7-yl (1), (3-noradamantyl)methyl (2), and 1-adamantyl (3) radicals. The three radicals model proposed intermediate surface radical structures in the chemical vapor deposition (CVD) of diamond on its 2 x 1 reconstructed [100] surface. The study finds that relatively low-level calculations previously applied to the problem of diamond growth are reliable, at least qualitatively.

  DOI：

  10.1021/jo971814+
• 作为产物：
  描述：

  金刚烷 在 sodium hydroxide 、 aluminum tri-bromide 、 溴 、 三溴化硼 作用下， 以 1,4-二氧六环 为溶剂， 反应 22.0h， 生成 7-亚甲基双环[3.3.1]壬-3-酮
  参考文献：
  名称：

  7-亚甲基双环[3.3.1]壬烷-3-one电还原环环反应的区域选择性

  摘要：

  在7-亚甲基双环[3.3.1]壬烷-3的非介导电还原中，发生竞争性跨环反应，得到7-甲基三环[3.3.1.03,7]壬烷-3-醇(5)和1-金刚烷醇(6) -N,N-二甲基甲酰胺中的一 (1)。反应区域选择性的明显温度依赖性可能归因于在羰基自由基阴离子的环化中动力学和热力学控制的竞争性操作。1•-、ΔΔH‡(5-exo - 6-endo)和ΔΔS‡(5-exo - 6-endo)的5-exo-和6-内环化之间的活化参数差异被评估为分别为 -3.1 kcal mol-1 和 -11 cal mol-1 K-1。还进行了半经验 PM3（RHF 和 UHF）计算以阐明反应机理。

  DOI：

  10.1246/bcsj.74.339

文献信息

• [EN] SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF<br/>[FR] COMPOSÉS PIPÉRIDINE À LIAISON ET SUBSTITUÉS PAR UNE QUINOXALINE, ET LEURS UTILISATIONS
  申请人：PURDUE PHARMA LP

  公开号：WO2010010458A1

  公开（公告）日：2010-01-28

  The invention relates to Substituted-Quinoxaline-Type Bridged-Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline- Type Bridged-Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Bridged-Piperidine Compound.

  这项发明涉及取代喹喔啉型桥式哌啶化合物，包括有效量的取代喹喔啉型桥式哌啶化合物的组合物，以及治疗或预防疼痛等疾病的方法，包括向需要治疗的动物施用有效量的取代喹喔啉型桥式哌啶化合物。
• Chemo-Selectivity of Group-VIII Metal Catalysts in Hydrogenation of Nonconjugated Enones
  作者：Jun-ichi Ishiyama、Satoshi Maeda、Kazuhiro Takahashi、Yasuhisa Senda、Shin Imaizumi

  DOI：10.1246/bcsj.60.1721

  日期：1987.5

  of group-VIII metal catalysts has been examined in the hydrogenation of nonconjugated enones at ambient temperature under an atmospheric pressure of hydrogen. A cobalt catalyst gave high yields of unsaturated alcohols from trialkylated olefinic ketones. Osmium showed the highest selectivity among platinum metal catalysts for the reduction of the carbonyl bond in the hydrogenation of trialkylated olefinic

  VIII族金属催化剂的化学选择性已在常温氢气压力下非共轭烯酮的氢化中得到检验。钴催化剂从三烷基化烯烃酮中得到高收率的不饱和醇。在铂金属催化剂中，锇在三烷基化烯烃酮的加氢反应中对羰基键的还原显示出最高的选择性。无论催化剂如何，单烷基化和二烷基化烯烃酮的氢化通常以烯烃官能团的优先饱和进行。4-亚甲基-和4-亚乙基环己酮的氢化伴随着在乙醇溶剂中在钌、铑和钯黑催化剂上形成二乙缩醛。在其他烯酮的氢化和其他催化剂上未检测到缩醛。此外，还研究了镍和钴催化剂对无环烯酮加氢的化学选择性。
• Highly Enantioselective Organocatalytic Oxidative Kinetic Resolution of Secondary Alcohols Using Chirally Modified AZADOs
  作者：Masaki Tomizawa、Masatoshi Shibuya、Yoshiharu Iwabuchi

  DOI：10.1021/ol900441f

  日期：2009.4.16

  A highly enantioselective organocatalytic oxidative kinetic resolution (OKR) of racemic secondary alcohols has been accomplished using asymmetric organocatalysis. A panel of chirally modified 2-azaadamantane N-oxyls (AZADOs) exhibit superior catalytic activity and high enantioselectivity, allowing us to obtain optically active secondary alcohols with a krel value up to 82.2.

  外消旋仲醇的高度对映选择性有机催化氧化动力学拆分（OKR）已使用不对称有机催化实现。一组手性改性的2-氮杂金刚烷N-氧基（AZADOs）表现出优异的催化活性和高对映选择性，使我们能够获得k rel值高达82.2的旋光仲醇。
• Oxa-adamantyl cannabinoids
  作者：Thanh C. Ho、Marcus A. Tius、Spyros P. Nikas、Ngan K. Tran、Fei Tong、Han Zhou、Nikolai Zvonok、Alexandros Makriyannis

  DOI：10.1016/j.bmcl.2021.127882

  日期：2021.4

  As a continuation of earlier work on classical cannabinoids bearing bulky side chains we report here the design, synthesis, and biological evaluation of 3'-functionalized oxa-adamantyl cannabinoids as a novel class of cannabinergic ligands. Key synthetic steps involve nucleophilic addition/transannular cyclization of aryllithium to epoxyketone in the presence of cerium chloride and stereoselective

  作为带有庞大侧链的经典大麻素早期工作的延续，我们在此报告了 3'-功能化氧杂金刚烷基大麻素作为一类新型大麻能配体的设计、合成和生物学评价。关键的合成步骤包括在氯化铈存在下芳基锂的亲核加成/跨环环化成环氧酮以及三环大麻素核的立体选择性构建。氧杂金刚烷基大麻素的合成很方便，并且易于扩大规模，从而可以制备足够数量的这些类似物以进行详细的体外评估。本文报道的新型 oxa-金刚烷基大麻素被发现是 CB1 和 CB2 大麻素受体的高亲和力配体。在环化酶测定中，这些化合物被发现是有效的 CB1 受体激动剂。异硫氰酸酯类似物 AM10504 能够不可逆地标记 CB1 和 CB2 受体。
• [EN] AZETIDINE-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE PIPÉRIDINE DE TYPE QUINOXALINE SUBSTITUÉE PAR UNE AZÉTIDINE ET LEURS UTILISATIONS
  申请人：PURDUE PHARMA LP

  公开号：WO2013080036A1

  公开（公告）日：2013-06-06

  The disclosure relates to Azetidine-Substituted Quinoxaline-Type Piperidine Compounds of Formula (I): and pharmaceutically acceptable derivatives thereof wherein the R1, R2, R3, Q, Y1, Z, A, B, a, and b are as defined herein, compositions comprising an effective amount of an Azetidine-Substituted Quinoxaline-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of an Azetidine-Substituted Quinoxaline-Type Piperidine Compound.

  该披露涉及公式(I)的氮杂环丙烷取代喹喔啉型哌啶化合物及其药用可接受的衍生物，其中R1、R2、R3、Q、Y1、Z、A、B、a和b如本文所定义，包含有效量氮杂环丙烷取代喹喔啉型哌啶化合物的组合物，以及治疗或预防疾病（如疼痛）的方法，包括向需要的动物施用有效量氮杂环丙烷取代喹喔啉型哌啶化合物。

表征谱图